Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, uncontrolled, multi-centre phase II study to investigate efficacy and safety of ONO-4538 in esophageal cancer patients

Next Previous
X
Search
Trial Profile

An open-label, uncontrolled, multi-centre phase II study to investigate efficacy and safety of ONO-4538 in esophageal cancer patients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Adenocarcinoma; Carcinoma; Oesophageal cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms AT-1; ATTRACTION-01; ATTRACTION-1
  • Sponsors Ono Pharmaceutical

    • Most Recent Events

    • 17 Jan 2021 Status changed from active, no longer recruiting to completed according results presented at the 2021 Gastrointestinal Cancers Symposium.
    • 17 Jan 2021 Results of final findings from AT-1 at a minimum follow-up of 5 years, presented at the 2021 Gastrointestinal Cancers Symposium
    • 01 May 2020 Results assessing Long-term efficacy and predictive correlates to Nivolumab treatement published in the Cancer Science

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top